University of St Andrews School of Medicine

LifeMD Appoints Dr. Joan LaRovere to its Board of Directors

Retrieved on: 
Friday, February 10, 2023
Machine learning, Entrepreneurship, MBA, Assistant, Environmental studies, Martin Trust Center for MIT Entrepreneurship, MIT Sloan School of Management, Pediatrics, Hospital, University of St Andrews School of Medicine, Harvard University, The Co Founder, Imperial College School of Medicine, Harvard Medical School, Virtu Foundation, Delhi Sikh Gurdwara Management Committee, First Nations in Ontario, United Nations, Artificial intelligence, Royal Brompton Hospital, Health care, LFMD, Innovation, Faculty, Boston, Pediatric intensive care unit, Columbia University, University, Management, Science, Genetics, Medicine

NEW YORK, Feb. 10, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the appointment of Dr. Joan LaRovere to its Board of Directors.

Key Points: 
  • NEW YORK, Feb. 10, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the appointment of Dr. Joan LaRovere to its Board of Directors.
  • With Dr. LaRovere’s appointment, LifeMD’s Board will comprise nine directors, seven of whom are independent.
  • “We are pleased to welcome Dr. LaRovere to the LifeMD Board,” said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD.
  • I believe that LifeMD has built a technology platform and affiliated medical group that will be a driving force in the next chapter of technology-enabled care in the United States and maybe beyond,” said Dr. Joan LaRovere.

UL Research Institutes Creates Materials Discovery Research Institute; Names Dr. Stuart R. Miller MDRI's Inaugural Vice President and Executive Director

Retrieved on: 
Tuesday, September 20, 2022
Science, Adoption, VP, Health, Safety, University of St Andrews School of Medicine, Research, Fire safety, Knowledge, CEO, Technology, School of Life Sciences (University of Dundee), Artificial intelligence, MDRI, Honeywell, Miller, UL, University, Education, UVSQ, Chemistry, Medical device, Management

Dr. Stuart R. Miller has been named MDRI's inaugural vice president and executive director.

Key Points: 
  • Dr. Stuart R. Miller has been named MDRI's inaugural vice president and executive director.
  • He brings extensive scientific experience and large team leadership to MDRI, supporting our ongoing efforts to increase the scale and scope of UL Research Institutes."
  • MDRI is the fifth research institute within the UL enterprise, joining the Chemical Insights, Digital Intelligence Safety, Electrochemical Safety and Fire Safety research institutes.
  • As inaugural executive director, Miller will steer the MDRI vision, oversee the institute's in-house research and expand collaboration with leading academic and other institutional research partners.

Global Biophotonics Markets Report 2022-2026 & 2031 Featuring Major Players - Thermo Fisher Scientific, OPGEN, NU Skin Enterprises, IPG Photonics, and Idex - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 22, 2022
Engineering, Technology, Other Technology, Manufacturing, Research, Science, Toshiba, Demography, Nu Skin Enterprises, Biology, Thermo Fisher Scientific, Integrative Production Technology for High-Wage Countries, Biotechnology, IDEX Corporation, Biophotonics, Growth, Procter & Gamble, University, Microscopy, University of St Andrews School of Medicine, Medicine, Application, Nanotechnology, Cell, Photon energy, Renewable energy, Microscope, Medical imaging

The "Biophotonics Global Market Report 2022, By Product Technology, By Application, By End Use" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biophotonics Global Market Report 2022, By Product Technology, By Application, By End Use" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the biophotonics market are Thermo Fisher Scientific, OPGEN, NU Skin Enterprises, IPG Photonics Corp., Idex Corp, Toshiba, Procter & Gamble, Horiba and Precision Photonics Corp.
    Where is the largest and fastest growing market for the global biophotonics market?
  • The Global Biophotonics Market market global report answers all these questions and many more.
  • The countries covered in the biophotonics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

Biophotonics Global Market Report 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 1, 2022
Health, Biotechnology, Growth, Biophotonics, Nu Skin Enterprises, Nanotechnology, University, Toshiba, Biotechnology, Procter & Gamble, IDEX Corporation, COVID-19, Medicine, University of St Andrews School of Medicine, Thermo Fisher Scientific, Biology, Photon energy, Microscope

The "Biophotonics Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biophotonics Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The biophotonics market consists of revenues generated from the sales of biophotonic instruments combining optics, nanotechnology, photonics, and biotechnology.
  • High prices of biophotonic-based devices or instruments are anticipated to limit the growth of the biophotonics market.
  • The increasing demand for minimally invasive surgeries is contributing to the growth of the biophotonics market.

Linneo Health appoints Don Bellamy as Chief Executive Officer

Retrieved on: 
Wednesday, September 29, 2021
Substance-related disorder, University of St Andrews School of Medicine, Novartis, TSX, Health, Patient, Medicine, Senior, Corporate services, Marketing, Knowledge, Growth, AstraZeneca, Cannabis, Research, University, Canopy Growth, Drug

Madrid, Spain 29 September 2021: Linneo Health, a global leader in the research, cultivation and supply of cannabis to improve human health and wellbeing, today announces the appointment of Don Bellamy as Chief Executive Officer.

Key Points: 
  • Madrid, Spain 29 September 2021: Linneo Health, a global leader in the research, cultivation and supply of cannabis to improve human health and wellbeing, today announces the appointment of Don Bellamy as Chief Executive Officer.
  • Don started his career in the pharmaceutical sector, where he held several positions of increasing responsibility in Baxalta-Shire, Novartis and AstraZeneca.
  • Don Bellamy, Chief Executive Officer of Linneo Health, commented: Linneo is a leader in the medicinal cannabis space, providing the highest quality product for partners developing cannabis-based therapies for people in need.
  • Alan Mackay, Chairman of Linneo Health, added: Don brings a wealth of knowledge and experience to Linneo Health from his decades working in the pharmaceutical and medical cannabis industries.

Linneo Health appoints Don Bellamy as Chief Executive Officer

Retrieved on: 
Wednesday, September 29, 2021
Substance-related disorder, University of St Andrews School of Medicine, Novartis, TSX, Health, Patient, Medicine, Senior, Corporate services, Marketing, Knowledge, Growth, AstraZeneca, Cannabis, Research, University, Canopy Growth, Drug

Madrid, Spain 29 September 2021: Linneo Health, a global leader in the research, cultivation and supply of cannabis to improve human health and wellbeing, today announces the appointment of Don Bellamy as Chief Executive Officer.

Key Points: 
  • Madrid, Spain 29 September 2021: Linneo Health, a global leader in the research, cultivation and supply of cannabis to improve human health and wellbeing, today announces the appointment of Don Bellamy as Chief Executive Officer.
  • Don started his career in the pharmaceutical sector, where he held several positions of increasing responsibility in Baxalta-Shire, Novartis and AstraZeneca.
  • Don Bellamy, Chief Executive Officer of Linneo Health, commented: Linneo is a leader in the medicinal cannabis space, providing the highest quality product for partners developing cannabis-based therapies for people in need.
  • Alan Mackay, Chairman of Linneo Health, added: Don brings a wealth of knowledge and experience to Linneo Health from his decades working in the pharmaceutical and medical cannabis industries.

ILC Therapeutics Announces Successful Completion of £3.5m Funding Round

Retrieved on: 
Monday, September 6, 2021
Biotechnology, Finance, Health, Professional Services, Pharmaceutical, ILC Therapeutics, Eos, Scottish Enterprise, ILC THERAPEUTICS, EOS, SCOTTISH ENTERPRISE

ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a ground-breaking new class of interferon drugs, announces the successful completion of a 3.5m pre- IPO funding round.

Key Points: 
  • ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a ground-breaking new class of interferon drugs, announces the successful completion of a 3.5m pre- IPO funding round.
  • Chairman Peter Bains said: We are very pleased to complete this important funding round and to strengthen the Board with the appointment of Robert Kopple, Professor David Harrison and Chris Brinsmead.
  • ILC Therapeutics Ltd is an emerging biotechnology company focused on modulating the innate immune system through the design and development of novel hybrid interferon drug candidates.
  • For more information on ILC Therapeutics, please visit: www.ilctherapeutics.com
    Follow ILC Therapeutics on LinkedIn: www.linkedin.com/company/ilctherapeutics/
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210906005255/en/